Melphalan flufenamide clinical trials
Also written Melflufen and Pepaxto.
How each study uses melphalan flufenamide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- 17 Aug 2022 · Pepaxti · EMEA/H/C/005681 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 1
Studies
Open first, then newest update. How each study uses melphalan flufenamide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Melflufen for Elderly Patients With Relapsed MyelomaWithdrawnPhase 2Fondazione EMN Italy OnlusNCT06682637Written as Melflufen
- A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to LenalidomideTerminatedPhase 3Oncopeptides ABNCT03151811Written as Melflufen
- Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple MyelomaTerminatedPhase 3Oncopeptides ABNCT04649060Written as Melflufen
- PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal FunctionTerminatedPhase 2Oncopeptides ABNCT03639610Written as Melflufen
- A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaCompletedPhase 2Oncopeptides ABNCT02963493Written as Melphalan flufenamide (Melflufen)
- A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) AmyloidosisTerminatedPhase 1Oncopeptides ABNCT04115956Written as Melphalan-Flufenamide (Melflufen)
- Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma PatientsTerminatedPhase 1/2Oncopeptides ABNCT01897714Written as Melflufen
Given beside what is tested · 1 — melphalan flufenamide is usual care or a partner of the new treatment
Codes
What other systems call melphalan flufenamide · ClinicalTrials.gg INT006393
- MeSH (NLM) C585069melphalan-flufenamideOne source NLM
- UNII (FDA) F70C5K4786MELPHALAN FLUFENAMIDEConfirmed FDA, NLM, Wikidata
- RxNorm 2531369One source FDA
- Wikidata Q27277739melphalan flufenamideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C107680Melphalan FlufenamideOne source FDA
- DrugBank DB16627One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C585069 | melphalan-flufenamide | One source NLM |
| UNII (FDA) | F70C5K4786 | MELPHALAN FLUFENAMIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2531369 | — | One source FDA |
| Wikidata | Q27277739 | melphalan flufenamide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C107680 | Melphalan Flufenamide | One source FDA |
| DrugBank | DB16627 | — | One source Wikidata |
Also registered as melphalan flufenamide hydrochloride (UNII 3412470A0V · RxNorm 2531370).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.